Status:
COMPLETED
Diltiazem in Jervell and Lange-Nielsen Syndrome
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Jervell and Lange Nielsen Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (...
Detailed Description
Subjects will be recruited by study personnel and will be scheduled for a single outpatient visit. If an implanted cardiac device (pacemaker or ICD) is in place, it will be interrogated to ensure no r...
Eligibility Criteria
Inclusion
- Age greater than 18 years
- Genetically confirmed diagnosis of Jervell and Lange-Nielsen syndrome
- Able to provide written informed consent
Exclusion
- Known hypersensitivity to diltiazem
- Pregnancy
- Congestive heart failure, angina, preexcitation, or chronic obstructive pulmonary disease
- Sick sinus syndrome or atrioventricular block in the absence of a pacemaker/defibrillator
- Any clinically significant ongoing medical or surgical condition that might jeopardize the subject's safety or interfere with the conduct of the study in the judgement of the investigator
- Baseline systolic blood pressure less than 100 Hg or diastolic blood pressure less than 60 Hg
Key Trial Info
Start Date :
October 16 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 23 2024
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT06534671
Start Date
October 16 2024
End Date
October 23 2024
Last Update
October 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232